#SootinClaimon.Com : ขอบคุณแหล่งข้อมูล : หนังสือพิมพ์ The Nation.
Experts demand generic version of drug effective against Covid-19
ColumnsApr 10. 2021
By Bobby Ramakant
Citizen News Service
Shouldn’t a medicine like Remdesivir, which has proved to be life-saving in certain cases of Covid-19, be made available to all those who need it without delay?
Even if Big Pharma has a patent, there are provisions in global trade treaties that allow governments to issue compulsory licences for such a life-saving drug, and keep public interest above profit. This is why medical experts are demanding that governments use compulsory licensing for generic production of such a drug to help save lives.
Compulsory licensing is one of the key public health and social justice safeguards that allows governments to use, produce, and import or export patented technologies in the public interest.
When confronted with intellectual property barriers that block access to affordable life-saving treatments, governments of countries like Thailand, Brazil, India, South Africa, Malaysia among others, have used this mechanism of compulsory licensing in the past, to ensure life-saving medicines reach the people who need it most (for HIV, hepatitis C, cancer, etc).
Compulsory licensing enables local production or importation of generic medicines, multiple supply options, reduces price and increases access to life-saving treatments for those most in need.
The Indian state of Maharashtra is registering high numbers of Covid-19 cases as of now, and the situation is equally bad in several states. Among the medicines that have shown to work in Covid-19 are steroids and Remdesivir. The patent owner of Remdesivir, Gilead, had given voluntary licence to six Indian pharmaceuticals. Even then, there is an acute shortage of Remdesivir injections, possibly due to hoarding and racketeering, especially in Maharashtra. This will have a cascading effect in the rest of India. Its maximum retail price ranges between 2,800-5,400 Indian rupees (Bt1,200-Bt2,500) as per the company that produces it, whereas procurement rates at hospitals range between 600-1000 rupees. “After we pointed out this discrepancy, the Maharashtra government has once again capped the price from 1,000 to 1,400 rupees per injection. Each eligible patient needs six doses and is required only for treating moderate or severe Covid cases” said Dr Ishwar Gilada, secretary-general of Organised Medicine Academic Guild (Omag), an umbrella network of several professional medical experts’ associations in India.
Omag has appealed to the Indian prime minister to put Remdesivir in Drug Price Control Order, as is done for other life-saving medicines. This will help reduce the maximum retail price to an affordable level and remove buffer margins and scope for black-marketing.
Another ask of Omag is to grant a compulsory licence under Section 84 of Indian Patents Act, 1970, to ramp-up production of Remdesivir. It can bring down procurement cost to below 500 rupees per vial, to save millions of Indian Covid patients as also several more globally, who will benefit from made-in-India generic Remdesivir.
Omag has also insisted on rationalising the use of Remedesivir with strict adherence to the guidelines, making multiple Remdesivir stores or Remdesivir banks with strict sales control, and making racketeering of Remdesivir punishable under the Epidemic Act of India.
Gilada, who is also the president of Aids Society of India and Governing Council member of International Aids Society, added that Remdesivir (GS-5734) was originally developed by Gilead Sciences in 2009, to treat Hepatitis C and respiratory syncytial virus, but failed. It was then repurposed and studied as a potential treatment for Ebola and Marburg virus infections. In collaborative study it was subsequently discovered that it had antiviral activity in-vitro against multiple filoviruses, pneumoviruses, paramyxoviruses, and coronaviruses. It is now repurposed for use in Covid-19. Remdesivir was granted a patent in India in 2010. A compulsory licence can be issued against any drug with a three-year-old patent and hence this demand from Omag.
One of the lessons from the global public health emergency, is that profiteering from illness has to end. It is an essential cog-in-the-wheel of sustainable development where no one is left behind and that all healthcare services reach every human being in a rights-based manner, not dependent on the capacity to pay.
Médecins Sans Frontières (MSF or Doctors Without Borders) had earlier stated that a compulsory licence is a licence for alternative production or importation of a generic version of a patented medicine which is granted by the government and does not require the consent of the patent-holder. The Doha Declaration on TRIPS Agreement and Public Health confirms that countries are free to determine the grounds of compulsory licences. TRIPS, or Trade-Related Aspects of Intellectual Property Rights, is an international legal agreement between all the member nations of the World Trade Organization. Examples of different grounds for compulsory licence include, for instance to remedy anti-competitive practices, failure to work or insufficient working of the patent, when the patented medicine is unaffordable or unavailable making it inaccessible to patients and when public health is at stake including but not limited to emergency/extreme urgency, epidemics and public non-commercial use.
Bobby Ramakant is a 2008 WNTD Awardee of the World Health Organization director-general.